Amylyx Pharmaceuticals Inc logo

Amylyx Pharmaceuticals (AMLX) — Congressional Trading Activity

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.

Members Trading

1

All-time in Amylyx Pharmaceuticals

Buyers vs Sellers

0Buyers/0Sellers

Members buying vs selling · last 90 days

Trades (90d)

0

Disclosed in the last 90 days

Avg Member Return

-65.8%

Top performers, TTM

Stock Report
$1K - $15K
StockPurchaseRepublicanNew YorkNov 16, 2022Oct 12, 2022House